We are live on ! Find out more

Micro Cap Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
XRTX
251
XORTX Therapeutics
XRTX
$3.74M
$3.74M $2.16 1.37%
JAGX icon
252
Jaguar Health
JAGX
$3.73M
$3.73M $0.7600 2.99%
MBRX icon
253
Moleculin Biotech
MBRX
$3.71M
$3.71M $0.5222 17.3%
RNAZ icon
254
TransCode Therapeutics
RNAZ
$3.57M
$3.57M $3.37 1.75%
JUNS
255
Jupiter Neurosciences
JUNS
$3.55M
$3.55M $4.61 1.91%
CRIS icon
256
Curis
CRIS
$3.49M
$3.49M $1.67 27.7%
GRI
257
GRI Bio
GRI
$3.45M
$3.45M $1.95 11.4%
ONCO icon
258
Onconetix
ONCO
$3.29M
$3.29M $0.8916 7.91%
SXTP icon
259
60 Degrees Pharmaceuticals
SXTP
$3M
$3M $1.13 0%
PPCB
260
Propanc Biopharma
PPCB
$2.76M
$2.76M $1.21 3.42%
ARTL icon
261
Artelo Biosciences
ARTL
$2.55M
$2.55M $0.7330 1.57%
CMND icon
262
Clearmind Medicine
CMND
$2.45M
$2.45M $1.65 2.48%
PPBT
263
Purple Biotech
PPBT
$2.41M
$2.41M $1.48 4.52%
GNPX icon
264
Genprex
GNPX
$2.39M
$2.39M $4.73 5.82%
VRAX icon
265
Virax Biolabs
VRAX
$2.22M
$2.22M $2.78 3.14%
DCOY
266
Decoy Therapeutics
DCOY
$1.92M
$1.92M $3.60 6.98%
CDT icon
267
CDT Equity Inc
CDT
$1.86M
$1.86M $2.94 0.68%
BDRX
268
Biodexa Pharmaceuticals
BDRX
$1.54M
$1.54M $1.50 5.06%
SCNI
269
Scinai Immunotherapeutics
SCNI
$1.28M
$1.28M $0.2470 4.66%
BBLG
270
Bone Biologics
BBLG
$1.19M
$1.19M $0.6580 27.6%
VIVS
271
VivoSim Labs
VIVS
$1.16M
$1.16M $0.3321 5.81%
VBIO
272
Valion Bio
VBIO
$938K
$938K $0.2260 27.1%
SLXN
273
Silexion Therapeutics
SLXN
$483K
$483K $0.4541 56.3%
7 8 9 10
11

Micro Cap Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 273 micro cap Biotechnology stocks — companies in the Biotechnology industry with a market cap under $250M — worth a combined $18.3B.

The largest by market cap are Greenwich LifeSciences (GLSI) at $248M, Adagene (ADAG) at $248M and Capricor Therapeutics (CAPR) at $243M.

Among institutional investors, Atrium Therapeutics (RNA) drew the most net new fund positions in Q1 2026: 162 funds opened new positions.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.